pembrolizumab based treatment for COVID-19: living meta-analysis of clinical studies

metastatic/adv melanoma (mML), pembrolizumab based treatment versus non platinum-based chemotherapy, meta-analysis of study results

Outcome	Relative effect 95%CI	LoD	Trt. better when		I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Degree of certainty	Endpoint importance	Published MA

no data for this filtering

0 randomized clinical trials; 0 observationnal studies

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.